Vasoseal hemostasis following coronary interventions with abciximab

Journal of Invasive Cardiology

Volumn 11, Issue SUPPL. B, 1999, Pages

  Lunney, Leo ^a  

^a Premier Heart Specialists   (United States)

Author keywords

Hemostasis; PTCA; REO

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; COLLAGEN; HEMOSTATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

AGED; APPARATUS, EQUIPMENT AND SUPPLIES; ARTICLE; FEMALE; FEMORAL ARTERY; HEART CATHETERIZATION; HEMOSTASIS; HUMAN; INJURY; INSTRUMENTATION; MALE; METHODOLOGY; MIDDLE AGED; MOBILIZATION; NEEDLESTICK INJURY; PILOT STUDY; POSTOPERATIVE HEMORRHAGE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COLLAGEN; EARLY AMBULATION; EQUIPMENT AND SUPPLIES; FEMALE; FEMORAL ARTERY; HEART CATHETERIZATION; HEMOSTATIC TECHNIQUES; HEMOSTATICS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; NEEDLESTICK INJURIES; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME;

EID: 0004184194     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. The EPIC investigators. Use of a monoclonal antibody directed against the platelet like protein Ilb/IIIa receptor in high risk coronary angioplasty. NEngUAfeJ 1994;330:956-96I.
2. The EPILOG investigators. Platelet glycoprotein Ilb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. NEngl J Med 1997;336:1686-1689.